Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 plus regorafenib in advanced or refractory solid tumors
CTR20201560Phase 2Terminated
- Sponsor
- CStone Pharmaceuticals
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab, regorafenib in Nonhematologic neoplasms, sponsored by CStone Pharmaceuticals. Started Aug 2020; status: terminated.
02
Drugs
sugemalimabregorafenib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20201560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201560.